Abstract
Craig M. Hales, Charles M. Heilig, Richard Chaisson, Stefan V. Goldberg, Fred Gordin, John L. Johnson, Grace Muzanyi, Jussi Saukkonen, Andrew Vernon, M. Elsa Villarino, William J. Burman
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications
1999
Unresolved referenced work
Kept as external metadata until matched
Surrogate markers and microbiologic end points
10.1086/653061 · 2010
Correlation between bacteriologic and clinical endpoints in trials of acute otitis media
10.1097/01.inf.0000092637.66762.c6 · 2003
A study of the impact of tuberculosis on the quality of life and the effect after treatment with dots
10.1177/1010539509336242 · 2009
Health-related quality of life trajectories among adults with tuberculosis: differences between latent and active infection
10.1378/chest.07-1494 · 2008
Measuring health-related quality of life in tuberculosis: a systematic review
10.1186/1477-7525-7-14 · 2009
Quality of life in tuberculosis: a review of the English language literature
10.1007/s11136-004-0374-1 · 2004
Personal and societal health quality lost to tuberculosis
10.1371/journal.pone.0005080 · 2009
Using the St. George respiratory questionnaire to ascertain health quality in persons with treated pulmonary tuberculosis
10.1378/chest.07-0755 · 2007
Once-weekly rifapentine and isoniazid versus twice-weekly rifampin and isoniazid in the continuation phase of therapy for drug-susceptible pulmonary tuberculosis: a prospective, randomized clinical trial among HIV-negative persons
10.1016/s0140-6736(02)09742-8 · 2002
Relapse with rifamycin monoresistant tuberculosis in HIV-infected patients treated with supervised once-weekly rifapentine and isoniazid
10.1016/s0140-6736(98)11467-8 · 1999
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis
10.1164/rccm.200603-360oc · 2006
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis
10.1164/rccm.200901-0078oc · 2009
Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis
10.1164/rccm.200503-417oc · 2006
Recurrent tuberculosis in the united states and canada: Relapse or reinfection?
10.1164/rccm.200408-1081oc · 2004
Unresolved referenced work
1994
R: A language and environment for statistical computing. 2.10.1 ed
2009
Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months
10.1164/ajrccm/147.4.1062 · 1993
Clinical symptoms and microbiological outcomes in tuberculosis treatment trials
10.1016/j.tube.2011.05.007 · 2011
Evaluation of new anti-infective drugs for the treatment and prevention of tuberculosis. Infectious Diseases Society of America and the Food and Drug Administration
10.1093/clind/15.supplement_1.s282 · 1992
No additional external references are available.